IDL Biotech signs distributor agreement in Ghana | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Typhiod fever

March 2021

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

Since its launch in Africa, the company has focused on finding the right partners for distribution. The company has previously announced that agreements have been signed with distributors in Uganda, Zimbabwe, Kenya, Rwanda, South Sudan and Somalia.

Now the company has also signed a distribution agreement with Res Health Consult Ltd for distribution in Ghana. The agreement covers the sale of the company’s rapid test; TUBEX® TF for typhoid fever.

Read the full press release here (Swedish)

IDL Biotech is making progress in Africa

IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company delivers TUBEX® TF.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech

Skip this intro